[go: up one dir, main page]

US20090023715A1 - Wound Healing - Google Patents

Wound Healing Download PDF

Info

Publication number
US20090023715A1
US20090023715A1 US12/176,782 US17678208A US2009023715A1 US 20090023715 A1 US20090023715 A1 US 20090023715A1 US 17678208 A US17678208 A US 17678208A US 2009023715 A1 US2009023715 A1 US 2009023715A1
Authority
US
United States
Prior art keywords
wound healing
alkyl
wound
optionally substituted
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/176,782
Inventor
Stanley Beams Brown
Cassandra Clare O'Grady
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photopharmica Ltd
Original Assignee
Photopharmica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photopharmica Ltd filed Critical Photopharmica Ltd
Priority to US12/176,782 priority Critical patent/US20090023715A1/en
Publication of US20090023715A1 publication Critical patent/US20090023715A1/en
Priority to US12/899,365 priority patent/US20110028459A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B5/00—Dyes with an anthracene nucleus condensed with one or more heterocyclic rings with or without carbocyclic rings
    • C09B5/24—Dyes with an anthracene nucleus condensed with one or more heterocyclic rings with or without carbocyclic rings the heterocyclic rings being only condensed with an anthraquinone nucleus in 1-2 or 2-3 position
    • C09B5/44—Azines of the anthracene series
    • C09B5/60—Thiazines; Oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system

Definitions

  • This invention relates to wound healing, the use of certain heterocyclic compounds and compositions and medicaments containing them in a wound healing process and for cosmetic uses.
  • the rate of chronic and acute wound healing can be delayed or impaired by a number of factors (exogenous and endogenous) and a variety of medical conditions. Examples include infection, ulceration particularly through diabetes, circulation problems associated with vascular disease, malnutrition, stress, cancer radiotherapy and/or chemotherapy, compromise of the immune system or simply due to the normal aging process. At present there is a clear need for therapeutic and cosmetic approaches that promote wound healing processes.
  • FIGS. 1A and 1B depict the results involving chronic leg ulcer.
  • the wound had shown no response to conventional treatments for 18 months prior to treatment with 3,7-bis(N,N-dibutylamino)phenothiazin-5-ium bromide and PDT.
  • FIGS. 2A and 2B depict results involving chronic leg ulcer.
  • the wound had shown no response to conventional treatments for 7 months prior to treatment with 3,7-bis(N,N-dibutylamino)phenothiazin-5-ium bromide and PDT
  • FIGS. 3A and 3B depict results involving chronic leg ulcer.
  • the wound had shown no response to conventional treatments for 14 months prior to treatment with 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide and PDT.
  • FIGS. 4A and 4B depict results involving chronic leg ulcer.
  • the wound had shown no response to conventional treatments for 3 months prior to treatment with 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide and PDT.
  • a phenothiazinium compound of Formula (1) for use in promoting wound healing in which the phenothiazinium compound is of Formula (1):
  • R 1 -R 6 each independently is selected from H, optionally substituted C 1-8 -alkyl, F, Cl, Br and I;
  • a and B each independently is selected from:
  • Q is selected from H and optionally substituted C 1-8 -alkyl
  • Z is selected from C(R a ) 2 , O, S, SO 2 , NR a in which each R a independently is selected from H and optionally substituted C 1-8 -alkyl;
  • R 7 and R 8 each independently is selected from H and optionally substituted C 1-8 -alkyl; Y is a counteranion; and p is 1, 2 or 3.
  • R 1 -R 8 , R a or Q is optionally substituted alkyl the optional substituents are preferably selected from aryl, particularly Ph; F; Cl; Br; I; OH; OC 1-4 -alkyl, particularly OCH 3 , OC 2 H 5 , OC 3 H 7 ; CN; OCOC 1-4 -alkyl, particularly OCOCH 3 ; optionally substituted C 3-6 -cycloalkyl particularly cyclohexyl, methyl-substituted cyclohexyl, cyclopentyl, and methyl-substituted cyclopentyl; COOH; COOC 1-4 -alkyl; SO 3 H;
  • R 1 -R 8 , R a or Q may be straight or branched chain and may optionally include C—C double or triple bonds.
  • R 1 -R 6 each independently is preferably selected from H, CH 3 , F, Cl, Br and I.
  • a and B are both NR 7 R 8 , R 7 and R 8 each independently preferably is selected from H and C 1-6 -alkyl optionally substituted by Ph, F, Cl, Br, I, OH, OCH 3 , OC 2 H 5 , OC 3 H 7 , CN, OCOCH 3 , cyclohexyl, methyl-substituted cyclohexyl, cyclopentyl, and methyl-substituted cyclopentyl.
  • Q is preferably H or CH 3 .
  • Z is preferably selected from CH 2 , O, S, SO 2 , NH, NCH 3 , NC 2 H 5 NCH 2 CH 2 OH and NCOCH 3 .
  • R a is preferably selected from H, CH 3 , C 2 H 5 , CH 2 CH 2 OH and COCH 3 .
  • Y may be an organic or inorganic counteranion is preferably selected from F ⁇ , Br ⁇ , Cl ⁇ , I ⁇ , NO 3 ⁇ , SCN ⁇ , ClO 3 ⁇ , ClO 4 ⁇ , IO 3 ⁇ , BF 4 ⁇ , HSO 4 ⁇ , H 2 PO 4 ⁇ , CH 3 SO 4 ⁇ , N 3 , SO 4 2 ⁇ , HPO 4 2 ⁇ , PO 4 3 ⁇ , acetate, lactate, citrate, tartrate, glycolate, glycerate, glutamate, ⁇ -hydroxyglutamate, glucouronate, gluconate, malate and aspartate.
  • R 7 and R 8 together with the nitrogen atom to which they are attached may form an optionally substituted 5-, 6- or 7-membered ring.
  • the groups R 1 and R 2 and/or R 4 and R 5 together with the carbon atoms to which they are attached may form an optionally substituted 5-, 6- or 7-membered ring.
  • the rings formed from one or both of R 7 and R 8 together with the nitrogen atom to which they are attached and from the groups R 1 and R 2 and/or R 4 and R 5 together with the carbon atoms to which they are attached may be saturated or unsaturated.
  • the optional substituents for the optionally substituted 5-, 6- or 7-membered rings formed from R 7 and R 8 together with the nitrogen atom to which they are attached, and formed from the groups R 1 and R 2 and/or R 4 and R 5 together with the carbon atoms to which they are attached may be selected from any of those substituents described above for R 1 .
  • methylene blue and ring substituted derivatives thereof and toluidine blue are excluded from the compounds of Formula (1).
  • a compound of Formula (1) for use as a wound healing agent is provided.
  • a wound healing agent comprising a compound of Formula (1) and a pharmaceutically acceptable diluent or excipient.
  • the present invention also provides a composition, preferably a pharmaceutical composition, for use in promoting wound healing that comprises a phenothiazinium compound of Formula (1) together with a diluent or excipient.
  • the medicament may be in a form for topical or systemic use and is preferably in a form for topical use.
  • the medicaments are preferably administered topically more preferably administered as a cream, suspension, emulsion, gel, ointment, salve, stick, soap, paste, or via an antimicrobial dressing such as a bandage impregnated with a compound of Formula (1) or a composition or medicament comprising a compound of Formula (1).
  • wound healing agents, compositions and medicaments provided by the present invention may comprise mixtures of two or more different compounds of Formula (1); they may also further comprise one or more different therapeutic or active agents.
  • a method for promoting wound healing in both chronic and acute wounds by applying or administering a phenothiazinium compound of Formula (1) to a wound site, and optionally exposing the wound site to light.
  • the method for promoting wound healing includes the following steps:
  • composition or medicament comprising a compound of Formula (1); b) applying or administering an effective amount of the composition or medicament to a wound area to be treated: and c) optionally exposing the wound area to light.
  • the compounds, compositions, wound healing agents and medicaments of the present invention may be used to treat any condition where the integrity of tissue is damaged, and thus covers chronic and acute wounds, wounds in connective tissue and wounds in muscle, bone and nerve tissue.
  • the wounds may include, but are not limited to the following: surgical wounds; bites; burns; acid and alkali burns; cold burn (frostbite), sun burn, minor cuts, major cuts, abrasions, lacerations, wounds caused by gunshot or knife injury; wounds caused by congenital disorders; wounds following dental surgery; periodontal disease; wounds following trauma; tumour associated wounds, which can be classified as malignant cutaneous ulcers related to the primary tumour or metastases; ulcers, leg ulcers; foot ulcers; pressure sores and corneal wounds.
  • Wounds can be classified by having either an acute or chronic etiology.
  • Acute wounds are caused by external damage to intact skin and include surgical wounds, bites, burns, cuts and abrasions, as well as more traumatic wounds such as lacerations and those caused by crush or gun shot injuries.
  • Chronic wounds are most frequently caused by endogenous mechanisms associated with a predisposing condition that ultimately compromises the integrity of dermal or epithelial tissue.
  • Pathophysiological abnormalities that may dispose to the formation of chronic wounds such as leg ulcers, foot ulcers, and pressure sores include compromised tissue perfusion as a consequence of impaired arterial supply (peripheral vascular disease) or impaired venous drainage (venous hypertension) and diseases such as diabetes mellitus.
  • Advancing age, obesity, smoking, poor nutrition and immunosuppression associated with disease (e.g., AIDS) or drugs (e.g. chemotherapy or radiation therapy) may also exacerbate chronic ulceration.
  • Pressure or decubitis ulcers have a different etiology from other chronic wounds in that they are caused by sustained external skin pressure, most commonly in the buttocks, sacrum, and heels. All chronic wounds heal slowly and in an unpredictable manner (Bowler et al., Clinical Microbiology Reviews, 14 (2) 244). For example, in a study of diabetic foot ulcers, with 20 weeks of good wound care only 31% of the ulcers healed (Margolis, et al. Diabetes Care, 22 (5), 692).
  • the present compounds, compositions, wound healing agents and medicaments, and method for promoting wound healing may be used any time from wound identification to treat chronic and acute wounds.
  • wounds that are associated with surgical interventions such times include pre-, during or post surgery, prior to surgical repair, and post surgical repair, to aid wound healing, preferably at a time from 0 to 7 days after, more preferably from 2 to 6 days after applying or administering the compound of Formula (1).
  • the area to be treated is optionally exposed to light, and where exposed to light, the time between application or administration of the compound and exposure to light is as defined below.
  • tissue welding tissue welding
  • tissue grafting including grafting used in transplant surgery.
  • They may be used to heal inflammatory disorders of the skin that result in itching, crusting, scaling or blisters, such as eczema, psoriasis and acne.
  • the method invention may also be used to treat forms of eczema for example those that result from a weakened immune response (allergy) such as atopic dermatitis.
  • compositions, wound healing agents and medicaments may need to be repeated and typically from 1 to 20 treatments may be applied, more preferably from 1 to 5 treatments to promote wound healing.
  • the compounds, compositions, wound healing agents, medicaments and methods described herein are preferably used for treating epithelial wounds, more preferably for treating skin wounds.
  • a cosmetic agent for example for uses in skin rejuvenation and thickening, reducing scar formation and birth mark removal.
  • a method that may be used for cosmetic purposes, including, but not limited to, skin rejuvenation and thickening, reducing scar formation and birth mark removal.
  • the cosmetic method includes the following steps:
  • the wound is an internal wound, such as a stomach ulcer
  • the compound, composition, wound healing agent or medicament may be applied via an endoscope and where it is desirable to expose the wound site to light this may be achieved by use of an endoscopic light source.
  • the compound of Formula (1) may be applied directly to the wound site or in a pharmaceutically acceptable composition, wound healing agent or medicament.
  • the compound, composition, wound healing agent or medicament may be administered locally or topically and delivered via a variety of means, for example via a spray, local injection, local infusion, cream, lotion, suspension, emulsion, gel, ointment, salve, stick, soap, liquid aerosol, powder aerosol, drops, paste, endoscopically or antimicrobial dressings such as bandages.
  • administration is topical, more preferably as a cream, suspension, emulsion, gel, ointment, salve, stick, soap, paste, or via an antimicrobial dressing, and especially as a cream, suspension, emulsion, gel or ointment.
  • the compounds of Formula (1) may be formulated into a variety of pharmaceutical compositions, wound healing agents or medicaments which contain the compounds and pharmaceutically acceptable carriers, excipients, adjuvants (each selected for certain characteristics that permit optimal formulation); these may include liposomes, nanoparticles, colloidal suspensions, micelles, microemulsions, vesicles and nanospheres.
  • compositions, wound healing agents or medicaments may also comprise further components such as conventional delivery vehicles and excipients including organic liquids such as alcohols (for example ethanol, propanol and isopropanol), dimethyl sulphoxide, glycols such as propylene glycol and polyethylene glycol, liquid, semi-solid and solid paraffins, water, saline, solubilisers such as castor oil derivatives for example ethoxylated castor oils like Cremophor EL (trade mark BASF AG) or Tween (trade mark, ICI Americas Inc.) types, Unguentum (trade mark, Merck KGaA), Solutol (trade mark, BASF AG), isotonising agents such as urea, glycerol, aminoethanol, propylene glycol, pH regulators, dyes, gelling agents, thickeners, buffers, hydrocarbon waxes and combinations thereof.
  • organic liquids such as alcohols (for example ethanol, propanol and isopropanol),
  • compositions of the invention may also optionally include other carriers, stabilizers, preservatives or adjuvants.
  • other carriers stabilizers, preservatives or adjuvants.
  • Remington The Science and Practice of Pharmacy , Lippincott, Williams & Wilkins (2005), which is incorporated by reference in its entirety.
  • composition, wound healing agents or medicaments may further comprise a mild reducing agent for example a sugar such as glucose or dextrose; ascorbic acid; sodium metabisulphite and nicotinamide adenine dinucleotide (NADH).
  • a mild reducing agent for example a sugar such as glucose or dextrose; ascorbic acid; sodium metabisulphite and nicotinamide adenine dinucleotide (NADH).
  • compositions, wound healing agents or medicaments are prepared by mixing a compound of Formula (1) with one or more pharmaceutically acceptable carriers at an appropriate temperature, typically from 15° to 40° C. at an appropriate pH, typically from pH 3 to 9 and preferably at a physiologically acceptable pH such as from pH 6.5 to 7.5.
  • the concentration of the compounds of Formula (1) in the compositions, wound healing agents or medicaments depends on the compound's photosensitising ability and is typically in the range from 0.001 to 20%.
  • Dry compositions, wound healing agents or medicaments which may be reconstituted before use are also provided in the present invention. These may be prepared by dry mixing solid components or preparing a liquid composition which is evaporated to dryness generally under mild conditions under vacuum or in low temperature ovens, freeze drying is a suitable drying technique.
  • the compounds of Formula (1) may also be administered systemically by any convenient means, for example intravenously, orally, sub-cutaneously, intramuscularly, directly into affected tissues and organs or intraperitoneally.
  • Application or administration by any of the means described above may need to be repeated and typically from 1 to 20 treatments may be applied, more preferably from 1 to 5 treatments to promote wound healing.
  • the dose rate of the compounds of Formula (1) for topical, direct or systemic administration is preferably in the range from 0.1 to 2000 ⁇ mol, preferably in the range 10 to 1000 ⁇ mol, more preferably from 50 to 500 ⁇ mol.
  • typical injections volumes are in the range 0.1 to 100 ml, preferably from 5 to 50 ml.
  • the light is preferably at wavelengths of 600-800 nm, more preferably at wavelengths from 630 nm to 700 nm
  • the light source may be any appropriate light source such as light emitting diode (LED), a laser or laser diode, a broad spectrum halogen lamp, or filtered lamp.
  • LED light emitting diode
  • laser laser or laser diode
  • broad spectrum halogen lamp or filtered lamp.
  • the light dose administered during PDT can vary but preferably is from 1 to 200 J/cm 2 , more preferably from 5 to 100 J/cm 2 , especially from 5 to 75 and ideally from 5 to 25 J/cm 2 .
  • Wound healing promotion may be achieved by applying or administering the drug alone or by applying or administering the drug and exposing to light.
  • light exposure may be at the time of drug administration or up to 12 hours after drug administration and the time may be tailored according to the wound being treated, the method of drug delivery and the specific compound of Formula (I) used.
  • Light exposure is preferably given at any time from the time of drug administration up to 3 hours, more preferably from the time of drug administration up to 1 hour.
  • the wound is preferably left occluded in the dark for up to 1 hour, more preferably from 1 to 20 minutes, and especially from 8 to 12 minutes before exposure to light.
  • Wound healing promotion may also be achieved by applying or administering the drug and exposing to light over many hours, for example where the drug is applied to a wound and a light source is included in a wound covering or dressing applied to the wound. Where light is applied over many hours this typically is a lower intensity light. The period where light is applied may be from 1 second to 100 hours.
  • Increasing the intensity (fluence rate) of the light dose generally reduces light exposure times.
  • exposure to light is localised to the area/region to be treated, and where wounds are being treated more preferably localised to the wound itself.
  • the wound may also be exposed intermittently to light, for example light exposures of 1 second up to 72 hours may be used with intermittent periods of 1 second up to 72 hours where there is no light exposure
  • the compounds of Formula (1) and compositions, wound healing agents and medicaments comprising compounds of Formula (1) may be used in the dark or on exposure to light to promote wound healing. In the dark it is the compound of Formula (1) alone that promotes wound healing.
  • wound healing promotion is achieved by applying or administering the drug and exposing to light.
  • phenothiazinium salts of Formula (1) may be synthesised as follows:
  • the solid formed is collected by filtration and purified by any suitable means such as by flash column chromatography over silica gel 60, using chloroform, chloroform/methanol (98/2) and then chloroform/methanol (90/10).
  • the product may be further purified by precipitation from chloroform with petroleum ether (b.p. 60-80° C.).
  • 2) Unsymmetrical phenothiazinium compounds where A ⁇ B a) Phenothiazine in chloroform is cooled to below 5° C. and a solution of iodine in chloroform added.
  • the solid formed is collected by filtration, washed with chloroform until free of iodine and then kept at room temperature under vacuum overnight to give phenothiazin-5-ium tetraiodide hydrate.
  • b) the phenothiazin-5-ium tetraiodide hydrate in methanol is added to a solution of an amine R 7 R 8 NH (in which R 7 and R 8 are as defined above). The reaction mixture is stirred overnight, reduced by evaporation and left to cool.
  • the solid that formed is collected by filtration, washed with diethyl ether and dried.
  • mice 6 control non diabetic mice (db/+), 6 control diabetic (db/db) mice and 6 (db/db) PDT treated diabetic mice.
  • Image Pro image analysis software (version 4.1.0.0, obtained from Media Cybernetics, USA) was used to calculate wound closure from wound images in each of the experimental groups over time. For each wound at each time point—open wound area was measured and expressed in terms of % wound area relative to day 4 (treatment day).
  • mice Control diabetic mice 100 71 PDT treated diabetic mice 100 46 (500 ⁇ M 3,7-bis(N,N- dibutylamino) phenothiazin-5- ium bromide in Unguentum M and 25 J/cm 2 ) Vehicle and light treated 100 67 diabetic mice (Unguentum M and 50 J/cm 2 ) 6 animals were included in each group.
  • 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide provides a substantial increase in the rate of wound healing when the control diabetic mice and treated diabetic mice are compared: 67% wound area remaining vs. 46% remaining respectively.
  • the wound healing in treated diabetic mice was improved and was comparable to the wound healing in the control non diabetic mice: 46% wound area remaining vs. 48% remaining respectively.
  • 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide was solubilised in ethanol to give a concentration of 10 mg/ml. This was diluted in Unguentum M: 80% water, to give creams with final concentrations of 100 ⁇ M or 500 ⁇ M of 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide.
  • the ulcer area was measured pre treatment and after 1 week and one month.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A phenothiazinium compound, compositions and medicaments for use in promoting wound healing and a method for promoting wound healing or cosmetic use by applying or administering a phenothiazinium compound to a wound site or the skin, and optionally exposing the wound site or skin to light.

Description

    FIELD OF THE INVENTION
  • This invention relates to wound healing, the use of certain heterocyclic compounds and compositions and medicaments containing them in a wound healing process and for cosmetic uses.
    • BACKGROUND INFORMATION
  • The rate of chronic and acute wound healing can be delayed or impaired by a number of factors (exogenous and endogenous) and a variety of medical conditions. Examples include infection, ulceration particularly through diabetes, circulation problems associated with vascular disease, malnutrition, stress, cancer radiotherapy and/or chemotherapy, compromise of the immune system or simply due to the normal aging process. At present there is a clear need for therapeutic and cosmetic approaches that promote wound healing processes.
  • The literature describes the PDT use of various photosensitisers in attempts to improve wound healing. For example, Photofrin (a porphyrin, Photofrin is a trade mark of Johnson & Johnson) showed delayed wound healing in rat skin flap reconstruction (Kubler et al Lasers in surgery and Medicine (1996), 18(4), 397-405. Parekh et al concluded in Lasers in surgery and Medicine (1999), 24(5), 375-381 that a benzoporphyrin and a phthalocyanine didn't alter wound healing. Lambrects et al concluded in Photochemical & Photobiological Sciences (2005), 4(7), 503-509 that a porphyrin delayed wound healing. Hamblin concluded in Journal of infectious diseases (2003), 187(11), 1717-25 that for a photosensitiser (Poly-lysine-chlorin e6) topical PDT did not accelerate wound healing, compared with that in untreated wounds. Belmont et al in the Laryngoscope (1999), 109(6), 886-90 using Photofrin concluded that PDT has been shown to delay wound healing. Heckenkamp et al in Journal of vascular surgery, (2000), 31(6), 1168-77 concludes that local photodynamic action of methylene blue exerts a retarding effect on intimal hyperplasia (one of the natural wound healing processes).
  • Compounds, methods and compositions/medicaments have now been identified which address these problems and provide a basis for promoting the wound healing process.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • The following figures represent exemplary embodiments of the invention and are not intended to be limiting.
  • FIGS. 1A and 1B depict the results involving chronic leg ulcer. The wound had shown no response to conventional treatments for 18 months prior to treatment with 3,7-bis(N,N-dibutylamino)phenothiazin-5-ium bromide and PDT.
  • FIGS. 2A and 2B depict results involving chronic leg ulcer. The wound had shown no response to conventional treatments for 7 months prior to treatment with 3,7-bis(N,N-dibutylamino)phenothiazin-5-ium bromide and PDT
  • FIGS. 3A and 3B depict results involving chronic leg ulcer. The wound had shown no response to conventional treatments for 14 months prior to treatment with 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide and PDT.
  • FIGS. 4A and 4B depict results involving chronic leg ulcer. The wound had shown no response to conventional treatments for 3 months prior to treatment with 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide and PDT.
    •  SUMMARY OF THE INVENTION
  • According to the present invention there is provided a phenothiazinium compound of Formula (1) for use in promoting wound healing, in which the phenothiazinium compound is of Formula (1):
  • Figure US20090023715A1-20090122-C00001
  • wherein:
    R1-R6 each independently is selected from H, optionally substituted C1-8-alkyl, F, Cl, Br and I;
    A and B each independently is selected from:
  • Figure US20090023715A1-20090122-C00002
  • in which:
  • Q is selected from H and optionally substituted C1-8-alkyl;
  • Z is selected from C(Ra)2, O, S, SO2, NRa in which each Ra independently is selected from H and optionally substituted C1-8-alkyl;
  • R7 and R8 each independently is selected from H and optionally substituted C1-8-alkyl;
    Y is a counteranion; and
    p is 1, 2 or 3.
    Where any one of R1-R8, Ra or Q is optionally substituted alkyl the optional substituents are preferably selected from aryl, particularly Ph; F; Cl; Br; I; OH; OC1-4-alkyl, particularly OCH3, OC2H5, OC3H7; CN; OCOC1-4-alkyl, particularly OCOCH3; optionally substituted C3-6-cycloalkyl particularly cyclohexyl, methyl-substituted cyclohexyl, cyclopentyl, and methyl-substituted cyclopentyl; COOH; COOC1-4-alkyl; SO3H;
  • The alkyl groups represented by R1-R8, Ra or Q may be straight or branched chain and may optionally include C—C double or triple bonds. R1-R6 each independently is preferably selected from H, CH3, F, Cl, Br and I.
  • Where A and B are both NR7R8, R7 and R8 each independently preferably is selected from H and C1-6-alkyl optionally substituted by Ph, F, Cl, Br, I, OH, OCH3, OC2H5, OC3H7, CN, OCOCH3, cyclohexyl, methyl-substituted cyclohexyl, cyclopentyl, and methyl-substituted cyclopentyl.
  • Q is preferably H or CH3.
    Z is preferably selected from CH2, O, S, SO2, NH, NCH3, NC2H5NCH2CH2OH and NCOCH3.
    Ra is preferably selected from H, CH3, C2H5, CH2CH2OH and COCH3.
    Y may be an organic or inorganic counteranion is preferably selected from F−, Br−, Cl−, I−, NO3 −, SCN−, ClO3 −, ClO4 −, IO3 −, BF4 −, HSO4 −, H2PO4 −, CH3SO4 −, N3, SO4 2−, HPO4 2−, PO4 3−, acetate, lactate, citrate, tartrate, glycolate, glycerate, glutamate, β-hydroxyglutamate, glucouronate, gluconate, malate and aspartate.
  • In compounds of Formula (1) where one or both of A and B is
  • Figure US20090023715A1-20090122-C00003
  • one or both of R7 and R8 together with the nitrogen atom to which they are attached may form an optionally substituted 5-, 6- or 7-membered ring. In compounds of Formula (1) the groups R1 and R2 and/or R4 and R5 together with the carbon atoms to which they are attached may form an optionally substituted 5-, 6- or 7-membered ring.
  • The rings formed from one or both of R7 and R8 together with the nitrogen atom to which they are attached and from the groups R1 and R2 and/or R4 and R5 together with the carbon atoms to which they are attached may be saturated or unsaturated.
  • The optional substituents for the optionally substituted 5-, 6- or 7-membered rings formed from R7 and R8 together with the nitrogen atom to which they are attached, and formed from the groups R1 and R2 and/or R4 and R5 together with the carbon atoms to which they are attached may be selected from any of those substituents described above for R1.
  • Preferably methylene blue and ring substituted derivatives thereof and toluidine blue are excluded from the compounds of Formula (1). According to a feature of the present invention there is provided a compound of Formula (1) for use as a wound healing agent.
  • According to a feature of the present invention there is provided a wound healing agent comprising a compound of Formula (1) and a pharmaceutically acceptable diluent or excipient.
  • The present invention also provides a composition, preferably a pharmaceutical composition, for use in promoting wound healing that comprises a phenothiazinium compound of Formula (1) together with a diluent or excipient.
  • According to a further feature of the present invention there is provided a use of a compound according to Formula (1) in the manufacture of a medicament for promoting wound healing.
    • DETAILED DESCRIPTION
  • The medicament may be in a form for topical or systemic use and is preferably in a form for topical use.
  • The medicaments are preferably administered topically more preferably administered as a cream, suspension, emulsion, gel, ointment, salve, stick, soap, paste, or via an antimicrobial dressing such as a bandage impregnated with a compound of Formula (1) or a composition or medicament comprising a compound of Formula (1).
  • The wound healing agents, compositions and medicaments provided by the present invention may comprise mixtures of two or more different compounds of Formula (1); they may also further comprise one or more different therapeutic or active agents.
  • According to a further feature of the present invention there is provided a method for promoting wound healing in both chronic and acute wounds by applying or administering a phenothiazinium compound of Formula (1) to a wound site, and optionally exposing the wound site to light.
  • More specifically the method for promoting wound healing includes the following steps:
  • a) preparing a composition or medicament comprising a compound of Formula (1);
    b) applying or administering an effective amount of the composition or medicament to a wound area to be treated: and
    c) optionally exposing the wound area to light.
  • The compounds, compositions, wound healing agents and medicaments of the present invention may be used to treat any condition where the integrity of tissue is damaged, and thus covers chronic and acute wounds, wounds in connective tissue and wounds in muscle, bone and nerve tissue.
  • The wounds may include, but are not limited to the following: surgical wounds; bites; burns; acid and alkali burns; cold burn (frostbite), sun burn, minor cuts, major cuts, abrasions, lacerations, wounds caused by gunshot or knife injury; wounds caused by congenital disorders; wounds following dental surgery; periodontal disease; wounds following trauma; tumour associated wounds, which can be classified as malignant cutaneous ulcers related to the primary tumour or metastases; ulcers, leg ulcers; foot ulcers; pressure sores and corneal wounds.
  • Wounds can be classified by having either an acute or chronic etiology. Acute wounds are caused by external damage to intact skin and include surgical wounds, bites, burns, cuts and abrasions, as well as more traumatic wounds such as lacerations and those caused by crush or gun shot injuries.
  • Chronic wounds are most frequently caused by endogenous mechanisms associated with a predisposing condition that ultimately compromises the integrity of dermal or epithelial tissue. Pathophysiological abnormalities that may dispose to the formation of chronic wounds such as leg ulcers, foot ulcers, and pressure sores include compromised tissue perfusion as a consequence of impaired arterial supply (peripheral vascular disease) or impaired venous drainage (venous hypertension) and diseases such as diabetes mellitus. Advancing age, obesity, smoking, poor nutrition and immunosuppression associated with disease (e.g., AIDS) or drugs (e.g. chemotherapy or radiation therapy) may also exacerbate chronic ulceration. Pressure or decubitis ulcers have a different etiology from other chronic wounds in that they are caused by sustained external skin pressure, most commonly in the buttocks, sacrum, and heels. All chronic wounds heal slowly and in an unpredictable manner (Bowler et al., Clinical Microbiology Reviews, 14 (2) 244). For example, in a study of diabetic foot ulcers, with 20 weeks of good wound care only 31% of the ulcers healed (Margolis, et al. Diabetes Care, 22 (5), 692).
  • The present compounds, compositions, wound healing agents and medicaments, and method for promoting wound healing may be used any time from wound identification to treat chronic and acute wounds. For wounds that are associated with surgical interventions, such times include pre-, during or post surgery, prior to surgical repair, and post surgical repair, to aid wound healing, preferably at a time from 0 to 7 days after, more preferably from 2 to 6 days after applying or administering the compound of Formula (1). After application or administration of the compound, composition, wound healing agent or medicament to the area to be treated, the area to be treated is optionally exposed to light, and where exposed to light, the time between application or administration of the compound and exposure to light is as defined below. They may also be used any time pre-, during or post in surgical procedures for example: tissue welding, skin grafting and tissue grafting including grafting used in transplant surgery. They may be used to heal inflammatory disorders of the skin that result in itching, crusting, scaling or blisters, such as eczema, psoriasis and acne. The method invention may also be used to treat forms of eczema for example those that result from a weakened immune response (allergy) such as atopic dermatitis.
  • Application or administration of the compounds, compositions, wound healing agents and medicaments may need to be repeated and typically from 1 to 20 treatments may be applied, more preferably from 1 to 5 treatments to promote wound healing.
  • The compounds, compositions, wound healing agents, medicaments and methods described herein are preferably used for treating epithelial wounds, more preferably for treating skin wounds.
  • According to a further feature of the present invention there is provided a cosmetic agent for example for uses in skin rejuvenation and thickening, reducing scar formation and birth mark removal.
  • According to a further feature of the present invention there is provided a method that may be used for cosmetic purposes, including, but not limited to, skin rejuvenation and thickening, reducing scar formation and birth mark removal. The cosmetic method includes the following steps:
  • a) preparing a composition comprising a compound of Formula (1);
    b) applying or administering an effective amount of the composition to an area to be treated: and
    c) optionally exposing the wound area to light.
  • Where the wound is an internal wound, such as a stomach ulcer, the compound, composition, wound healing agent or medicament may be applied via an endoscope and where it is desirable to expose the wound site to light this may be achieved by use of an endoscopic light source.
  • The compound of Formula (1) may be applied directly to the wound site or in a pharmaceutically acceptable composition, wound healing agent or medicament. The compound, composition, wound healing agent or medicament may be administered locally or topically and delivered via a variety of means, for example via a spray, local injection, local infusion, cream, lotion, suspension, emulsion, gel, ointment, salve, stick, soap, liquid aerosol, powder aerosol, drops, paste, endoscopically or antimicrobial dressings such as bandages. Preferably administration is topical, more preferably as a cream, suspension, emulsion, gel, ointment, salve, stick, soap, paste, or via an antimicrobial dressing, and especially as a cream, suspension, emulsion, gel or ointment.
  • The compounds of Formula (1) may be formulated into a variety of pharmaceutical compositions, wound healing agents or medicaments which contain the compounds and pharmaceutically acceptable carriers, excipients, adjuvants (each selected for certain characteristics that permit optimal formulation); these may include liposomes, nanoparticles, colloidal suspensions, micelles, microemulsions, vesicles and nanospheres.
  • The compositions, wound healing agents or medicaments may also comprise further components such as conventional delivery vehicles and excipients including organic liquids such as alcohols (for example ethanol, propanol and isopropanol), dimethyl sulphoxide, glycols such as propylene glycol and polyethylene glycol, liquid, semi-solid and solid paraffins, water, saline, solubilisers such as castor oil derivatives for example ethoxylated castor oils like Cremophor EL (trade mark BASF AG) or Tween (trade mark, ICI Americas Inc.) types, Unguentum (trade mark, Merck KGaA), Solutol (trade mark, BASF AG), isotonising agents such as urea, glycerol, aminoethanol, propylene glycol, pH regulators, dyes, gelling agents, thickeners, buffers, hydrocarbon waxes and combinations thereof. The compositions of the invention may also optionally include other carriers, stabilizers, preservatives or adjuvants. For typical examples of these classes of compounds, see Remington: The Science and Practice of Pharmacy, Lippincott, Williams & Wilkins (2005), which is incorporated by reference in its entirety.
  • The composition, wound healing agents or medicaments may further comprise a mild reducing agent for example a sugar such as glucose or dextrose; ascorbic acid; sodium metabisulphite and nicotinamide adenine dinucleotide (NADH).
  • Typically the compositions, wound healing agents or medicaments are prepared by mixing a compound of Formula (1) with one or more pharmaceutically acceptable carriers at an appropriate temperature, typically from 15° to 40° C. at an appropriate pH, typically from pH 3 to 9 and preferably at a physiologically acceptable pH such as from pH 6.5 to 7.5.
  • The concentration of the compounds of Formula (1) in the compositions, wound healing agents or medicaments depends on the compound's photosensitising ability and is typically in the range from 0.001 to 20%.
  • Dry compositions, wound healing agents or medicaments which may be reconstituted before use, are also provided in the present invention. These may be prepared by dry mixing solid components or preparing a liquid composition which is evaporated to dryness generally under mild conditions under vacuum or in low temperature ovens, freeze drying is a suitable drying technique.
  • The compounds of Formula (1) may also be administered systemically by any convenient means, for example intravenously, orally, sub-cutaneously, intramuscularly, directly into affected tissues and organs or intraperitoneally.
  • Application or administration by any of the means described above may need to be repeated and typically from 1 to 20 treatments may be applied, more preferably from 1 to 5 treatments to promote wound healing.
  • The dose rate of the compounds of Formula (1) for topical, direct or systemic administration is preferably in the range from 0.1 to 2000 μmol, preferably in the range 10 to 1000 μmol, more preferably from 50 to 500 μmol. For systemic administration such as by injection typical injections volumes are in the range 0.1 to 100 ml, preferably from 5 to 50 ml.
  • Where wound healing is promoted on exposure to light the light is preferably at wavelengths of 600-800 nm, more preferably at wavelengths from 630 nm to 700 nm
  • The light source may be any appropriate light source such as light emitting diode (LED), a laser or laser diode, a broad spectrum halogen lamp, or filtered lamp.
  • The light dose administered during PDT can vary but preferably is from 1 to 200 J/cm2, more preferably from 5 to 100 J/cm2, especially from 5 to 75 and ideally from 5 to 25 J/cm2.
  • Wound healing promotion may be achieved by applying or administering the drug alone or by applying or administering the drug and exposing to light.
  • Generally, where light exposure is given this may be at the time of drug administration or up to 12 hours after drug administration and the time may be tailored according to the wound being treated, the method of drug delivery and the specific compound of Formula (I) used. Light exposure is preferably given at any time from the time of drug administration up to 3 hours, more preferably from the time of drug administration up to 1 hour. Where the phenothiazinium compound is administered topically the wound is preferably left occluded in the dark for up to 1 hour, more preferably from 1 to 20 minutes, and especially from 8 to 12 minutes before exposure to light.
  • Wound healing promotion may also be achieved by applying or administering the drug and exposing to light over many hours, for example where the drug is applied to a wound and a light source is included in a wound covering or dressing applied to the wound. Where light is applied over many hours this typically is a lower intensity light. The period where light is applied may be from 1 second to 100 hours.
  • Increasing the intensity (fluence rate) of the light dose generally reduces light exposure times.
  • It is preferred that exposure to light is localised to the area/region to be treated, and where wounds are being treated more preferably localised to the wound itself.
  • After applying or administering the drug the wound may also be exposed intermittently to light, for example light exposures of 1 second up to 72 hours may be used with intermittent periods of 1 second up to 72 hours where there is no light exposure
  • The compounds of Formula (1) and compositions, wound healing agents and medicaments comprising compounds of Formula (1) may be used in the dark or on exposure to light to promote wound healing. In the dark it is the compound of Formula (1) alone that promotes wound healing.
  • In preferred embodiments of the present inventions wound healing promotion is achieved by applying or administering the drug and exposing to light.
  • The phenothiazinium salts of Formula (1) may be synthesised as follows:
  • 1) Symmetrical phenothiazinium compounds where A=B
    a) Phenothiazine is firstly brominated with bromine in glacial acetic acid to give 3,7-dibromophenothiazin-5-ium bromide, the suspension formed is collected by filtration.
    b) the 3,7-dibromophenothiazin-5-ium bromide is added to an amine represented by R7R8NH (in which R7 and R8 are as defined above) or an N-heterocycle in chloroform. The solid formed is collected by filtration and purified by any suitable means such as by flash column chromatography over silica gel 60, using chloroform, chloroform/methanol (98/2) and then chloroform/methanol (90/10). The product may be further purified by precipitation from chloroform with petroleum ether (b.p. 60-80° C.).
    2) Unsymmetrical phenothiazinium compounds where A≠B
    a) Phenothiazine in chloroform is cooled to below 5° C. and a solution of iodine in chloroform added. The solid formed is collected by filtration, washed with chloroform until free of iodine and then kept at room temperature under vacuum overnight to give phenothiazin-5-ium tetraiodide hydrate.
    b) the phenothiazin-5-ium tetraiodide hydrate in methanol is added to a solution of an amine R7R8NH (in which R7 and R8 are as defined above). The reaction mixture is stirred overnight, reduced by evaporation and left to cool. The solid that formed is collected by filtration, washed with diethyl ether and dried.
    c) triethylamine in dichloromethane followed by a solution of a different second amine R7R8NH (in which R7 and R8 are as defined above) in dichloromethane is added to a solution of the solid from b) above in dichloromethane. The reaction mixture is stirred overnight, the organic layer washed with dilute hydrochloric acid and water, separated and dried (MgSO4). The majority of the solvent is evaporated and diethyl ether added to precipitate the product which is collected by filtration, washed with diethyl ether and dried. Further purification of the product, if necessary, may be by flash column chromatography as described in 1b) above.
    • EXAMPLES Example 1 A Study to Investigate the Effect of 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide PDT on Wound Healing in Spontaneous Diabetic Mutation (Strain c57BLKs/Bom db/db Obtainable from Taconic, Denmark) Mice Background
  • When wounds are created on non diabetic (db/+) mice they heal quickly. When wounds are created on (db/db) diabetic mice the wounds heal more slowly compared to the non diabetic mice. This delayed healing may be caused by a lack of vasculature to feed the wound. The delayed healing model is representative of a chronic wound, and wound healing effects of drugs can be more closely monitored and more easily measured.
    • Materials and Methods
  • 18 animals were included in this study. 6 control non diabetic mice (db/+), 6 control diabetic (db/db) mice and 6 (db/db) PDT treated diabetic mice.
  • The 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide was formulated in ethanol and Unguentum M as described in Example 2 below at a concentration of 0.266 mg/mL.
    • Procedure
  • On day 0, the animals were anaesthetised and a single standardised full thickness wound (7.5 mm×7.5 mm) was created in the flank skin of each experimental animal. Wounds were then dressed with a 1.5×1.5 cm pad of encapsulated gauze moistened with a fixed volume of sterile saline solution. Wounds were allowed to heal without intervention for a period of 4 days, other than the replacement of saline moistened gauze and film dressings as required.
  • On day 4 dressings were removed. For the PDT treated group 100 mg of 0.266 mg/mL 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide cream was applied to the wound The wound was then covered and left for 6 minutes and 40 seconds. Following this, the wound was illuminated with 688 nm light, at a fluence rate of 125 mW/cm2 to give a light dose of 25 J/cm2. No drug or light was given to the control animals.
  • Dressings were reapplied immediately after treatment and subsequently on post-wounding days 7 & 10.
  • Immediately after wounding (day 0) and subsequently on days 4 and 7 all the wounds were digitally photographed together with a calibration/identity plate.
  • Image Pro image analysis software (version 4.1.0.0, obtained from Media Cybernetics, USA) was used to calculate wound closure from wound images in each of the experimental groups over time. For each wound at each time point—open wound area was measured and expressed in terms of % wound area relative to day 4 (treatment day).
  • Results
    % wound area
    3 days post
    Treatment day treatment
    Control non diabetic mice 100 48
    Control diabetic mice 100 71
    PDT treated diabetic mice 100 46
    (500 μM 3,7-bis(N,N-
    dibutylamino) phenothiazin-5-
    ium bromide in Unguentum M
    and 25 J/cm2)
    Vehicle and light treated 100 67
    diabetic mice (Unguentum M
    and 50 J/cm2)
    6 animals were included in each group.
  • Thus in combination with light 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide provides a substantial increase in the rate of wound healing when the control diabetic mice and treated diabetic mice are compared: 67% wound area remaining vs. 46% remaining respectively. In addition the wound healing in treated diabetic mice was improved and was comparable to the wound healing in the control non diabetic mice: 46% wound area remaining vs. 48% remaining respectively.
    • Example 2 A Study to Investigate the Effect of 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide PDT on Wound Healing in Wistar Rat
  • 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide was solubilised in ethanol to give a concentration of 10 mg/ml. This was diluted in Unguentum M: 80% water, to give creams with final concentrations of 100 μM or 500 μM of 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide.
    • Treatment Method
  • The above creams were used on the closure of full thickness excisional wounds in Wistar rats with exposure to light. The effect of topical application of 50 mg of 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide (at concentrations of 100 μM and 500 μM) followed by photo-activation with 688 nm laser light was investigated and compared to that of application of the drug delivery vehicle (Unguentum M) followed by 688 nm photo-activation. The light dose used was 50 J/cm2. Wound repair was measured in terms of the closure of standardised full-thickness excisional wounds created in the flank skin of adult Wistar rats.
  • At the lower dose (100 μM) wounds in receipt of light treatment closed more rapidly than similar wounds in receipt of the 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide alone.
  • At the higher dose of 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide (i.e. 500 μM) wounds closed more rapidly than similar wounds in receipt of the lower dose. From gross examination of wound and wound margin tissue—no adverse tissue responses were noted consequent to any treatment regime followed in this study.
    • Example 3 A Clinical Study to Investigate the Effect of 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide PDT on the Wound Healing of Chronic Ulcers Materials and Methods
  • After ethical review board approval and written informed participant consents were obtained, patients were recruited, provided they satisfied the ethically approved inclusion criteria. MHRA approval had been obtained.
  • Patients were recruited who had chronic non healing leg ulcers or diabetic foot ulcers. These patients had shown little or no wound healing for a number of weeks prior to treatment.
    • Procedure
  • For the treatment 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide, formulated in ethanol and Unguentum M as described in Example 2 above at 500 μM, was applied topically to the ulcer surface and surrounding ulcer margin (5 mm) giving a cream depth of up to 5 mm. The ulcer was then left, not occluded, but in minimal lighting, for 15 minutes. After this pre-incubation time, the cream was rubbed into the ulcer so underlying skin/tissue could be seen through the cream. If this was not possible excess cream was removed. The ulcer was then illuminated using a broad band CureLight lamp (obtainable from PhotoCure) at a fluence rate of 20-50 mW/cm2 giving a total light dose of 50 J/cm2.
  • The ulcer area was measured pre treatment and after 1 week and one month.
    • Results
  • There was a reduction in the area of the treated ulcers following the photodynamic treatment. This is shown in Table 1.
  • TABLE 1
    Percentage reduction in ulcer area after 1
    week and 1 month compared to pre treatment.
    Percentage reduction at 1 Percentage reduction at 1
    Patient week month
    1 0 10
    2 Not measured 50
    3 23 34
    4 8 13
    5 14 8
    • Example 4 A Study to Investigate the Effect of 100 μM and 500 μM 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide on Wound Healing in the Wistar Rat Materials and Methods
  • On day 0, animals were anaesthetised and a single standardised full thickness wound (7.5 mm×7.5 mm) was created in the flank skin of each experimental animal. Wounds were dressed with a 1.5×1.5 cm pad of encapsulated gauze moistened with a fixed volume of sterile saline. Wounds were allowed to heal without intervention for a period of 4 days, other than the replacement of saline moistened gauze and film dressings, as required.
  • On day 4 standard secondary dressings were removed. 100 mg of 100 μM or 500 μM 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide cream was applied to the wound. The wounds were not illuminated. The area of the wounds were measured prior to treatment (day 4) and on day 6, 8 and 10.
  • Results
    % Wound area remaining, no light
    2 days post 4 days post 6 days post
    treatment treatment treatment
    100 μM 62 33 25
    500 μM 62 30 19
  • In control tests the cream vehicle used alone had no effect on wound healing. In general terms the wounds heal faster at a 500 μM concentration than at 100 μM.
    • Example 5 Phase IIa Randomised, Placebo Controlled Trial to Investigate Wound Healing Using Photodynamic Therapy in Chronic Leg Ulcers Trial Design
  • 16 patients with chronic leg ulcers were recruited for the study. All patients had ulcers that had been present for at least 3 months prior to treatment. After randomisation, 8 patients were treated with 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide PDT and 8 patients were treated with placebo. Ulcer area was measured before treatment and at 1 week, 1 month, 2 months and 3 months post treatment using a Visitrak system. Photographs were taken of the ulcers before treatment and at 24 h, 1 week, 1, 2 and 3 months post treatment.
    • Methodology
  • Placebo cream was Unguentum Merck:water (1:2). 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide cream was 500 μM 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide in Unguentum Merck:water (1:2). For the treatment a 1 mm depth of cream was spread over the surface of the ulcer. The ulcer was then left, occluded under film, shielded from light for 15 minutes. At the end of the 15 minute incubation, excess cream was removed and the ulcer was illuminated using a CureLight 01 (obtainable from Photocure) at a light dose of 50 J/cm2.
    • Results: Chronic Leg Ulcers
  • Better healing, as measured by the size of the wound, was found in patients with chronic leg ulcers treated with 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide compared to those treated with placebo. At 2 months, 2 out of 8 (25%) patients who received 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide showed complete wound healing compared to none of those who received placebo. At 3 months, 4 out of 8 (50%) patients who received 3,7-bis(N,N-dibutylamino) phenothiazin-5-ium bromide showed complete wound healing compared to 1 out of 8 (12.5%) patients who received placebo.
  • Although any methods and materials, similar or equivalent to those described herein, can be used in the practice or testing of the present invention, the preferred methods and materials are described herein. All publications, patents and patent applications cited herein are incorporated herein by reference for the purpose of disclosing and describing specific aspects of the invention for which the publication is cited.

Claims (13)

1-9. (canceled)
10. A method of cosmetic treatment comprising:
a) applying or administering to an area to be treated an effective amount of a composition comprising a compound of Formula (I)
Figure US20090023715A1-20090122-C00004
wherein:
R1-R6 each independently is selected from H, optionally substituted C1-6-alkyl, F, Cl, Br and I;
A and B each independently is selected from:
Figure US20090023715A1-20090122-C00005
wherein:
Q is selected from H and optionally substituted C1-4-alkyl;
Z is selected from C(Ra)2, O, S, SO2 and NRa in which Ra is selected from H and optionally substituted C1-4-alkyl;
R7 and R8 each independently is selected from H and optionally substituted C1-6-alkyl;
Y is a counteranion; and
p is 1, 2 or 3; and
b) optionally exposing the treated area to light.
11. The method according to claim 10, wherein said cosmetic treatment is selected from skin rejuvenation, skin thickening, reduction of scar formation and birth mark removal.
12. The method according to claim 10, wherein said cosmetic treatment is skin rejuvenation.
13. The method according to claim 10, wherein said cosmetic treatment is skin thickening.
14. The method according to claim 10, wherein said cosmetic treatment is reduction of scar formation.
15. The method according to claim 10, wherein said cosmetic treatment is birth mark removal.
16. The method according to claim 10, wherein said composition further comprises a pharmaceutically acceptable diluent or excipient.
17. The method according to claim 10, wherein R7 and R8 are independently selected from optionally-substituted C3-6 alkyl.
18. The method according to claim 10, wherein A and B are of formula —NR7R8.
19. The method according to claim 10, wherein Y is a counterion selected from F−, Br−, Cl−, I−, NO3 −, SCN−, ClO3 −, ClO4 −, IO3 −, BF4 −, HSO4 −, H2PO4 −, CH3SO4 −, N3, SO4 2−, HPO4 2−, PO4 3−, acetate, lactate, citrate, tartrate, glycolate, glycerate, glutamate, β-hydroxyglutamate, glucouronate, gluconate, malate and aspartate.
20. The method according to claim 10, wherein R1, R2, R3, R4, R5 and R6 each represents H, and A and B represent —NR7R8 wherein R7 and R8 represent butyl.
21. A method of cosmetic treatment comprising:
a) applying or administering to an area to be treated an effective amount of a composition comprising a compound of Formula (1)
Figure US20090023715A1-20090122-C00006
wherein:
R1-R6 each independently is selected from H, optionally substituted C1-6-alkyl, F, Cl, Br and I;
A and B each independently is selected from:
Figure US20090023715A1-20090122-C00007
wherein:
Q is selected from H and optionally substituted C1-4-alkyl;
Z is selected from C(Ra)2, O, S, SO2, NRa in which Ra is selected from H and optionally substituted C1-4-alkyl;
R7 and R8 each independently is selected from optionally substituted C3-6-alkyl;
Y is a counteranion; and
p is 1, 2 or 3; and
b) optionally exposing the treated area to light.
US12/176,782 2004-09-20 2008-07-21 Wound Healing Abandoned US20090023715A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/176,782 US20090023715A1 (en) 2004-09-20 2008-07-21 Wound Healing
US12/899,365 US20110028459A1 (en) 2004-09-20 2010-10-06 Wound Healing

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0420888A GB0420888D0 (en) 2004-09-20 2004-09-20 Compounds and uses
GB0420888.8 2004-09-20
PCT/GB2005/003536 WO2006032847A1 (en) 2004-09-20 2005-09-14 Wound healing
US11/723,523 US7407953B2 (en) 2004-09-20 2007-03-20 Wound healing
US12/176,782 US20090023715A1 (en) 2004-09-20 2008-07-21 Wound Healing

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/723,523 Division US7407953B2 (en) 2004-09-20 2007-03-20 Wound healing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/899,365 Continuation US20110028459A1 (en) 2004-09-20 2010-10-06 Wound Healing

Publications (1)

Publication Number Publication Date
US20090023715A1 true US20090023715A1 (en) 2009-01-22

Family

ID=33306894

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/723,523 Expired - Fee Related US7407953B2 (en) 2004-09-20 2007-03-20 Wound healing
US12/176,782 Abandoned US20090023715A1 (en) 2004-09-20 2008-07-21 Wound Healing
US12/899,365 Abandoned US20110028459A1 (en) 2004-09-20 2010-10-06 Wound Healing

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/723,523 Expired - Fee Related US7407953B2 (en) 2004-09-20 2007-03-20 Wound healing

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/899,365 Abandoned US20110028459A1 (en) 2004-09-20 2010-10-06 Wound Healing

Country Status (11)

Country Link
US (3) US7407953B2 (en)
EP (1) EP1797053B1 (en)
JP (1) JP5118967B2 (en)
AT (1) ATE486860T1 (en)
CY (1) CY1111177T1 (en)
DE (1) DE602005024590D1 (en)
DK (1) DK1797053T3 (en)
ES (1) ES2358760T3 (en)
GB (1) GB0420888D0 (en)
PT (1) PT1797053E (en)
WO (1) WO2006032847A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151831A1 (en) * 2009-06-25 2010-12-29 Savient Pharmaceuticals, Inc. Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US10160958B2 (en) 2005-04-11 2018-12-25 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
WO2023229659A3 (en) * 2021-10-21 2024-03-14 The General Hospital Corporation Photonic antimicrobial wound surface dressing
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0113121D0 (en) * 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
ATE539733T1 (en) 2005-11-09 2012-01-15 Klox Technologies Inc COMPOSITIONS AND METHODS FOR TOOTH WHITENING
EP2368598A1 (en) 2006-04-28 2011-09-28 Ondine International Holdings Ltd. Photodisinfection devices and methods
US20100266989A1 (en) 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
KR20150072458A (en) 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
CN101631780A (en) * 2007-04-03 2010-01-20 普罗瑟塔生物谐成公司 Phenothiazine derivatives for antiviral therapy
BRPI0801368A8 (en) * 2008-05-12 2021-03-23 Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp stabilization processes of cation radicals of phenothiazine compounds, cosmeceutical formulations, uses of phenothiazine compounds in the preparation of cosmeceutical formulations and methods of preventing diseases and skin disorders
SI2352488T1 (en) 2008-11-07 2017-07-31 Klox Technologies Inc. Oxidative photoactivated skin rejuvenation composition comprising hyaluronic acid, glucosamine, or allantoin
US20100166677A1 (en) 2008-12-30 2010-07-01 Avon Products, Inc. Use of Tiliacora Triandra in Cosmetics and Compositions Thereof
PL2453922T3 (en) 2009-07-17 2018-03-30 Klox Technologies Inc. ANTIBACTERIAL ORAL COMPOSITION
ES2675879T3 (en) * 2009-12-22 2018-07-13 Rigshospitalet, Copenhagen University Hospital Wound care products
CA2799223C (en) * 2010-06-30 2019-02-26 Avon Products, Inc. Compositions and methods for stimulating magp-1 to improve the appearance of skin
US8759336B2 (en) 2011-03-17 2014-06-24 Prosetta Antiviral Inc. Antiviral compounds
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
US20130103123A1 (en) 2011-10-14 2013-04-25 Sazzadur Rahman Khan Light-Emitting Devices for Wound Healing
WO2013151994A1 (en) * 2012-04-02 2013-10-10 Health Research, Inc. Compositions and methods comprising toll like receptor (tlr) stimulating agents for prophylaxis and therapy for damage to dermal epithelium
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US11116841B2 (en) 2012-04-20 2021-09-14 Klox Technologies Inc. Biophotonic compositions, kits and methods
BR112015005593B1 (en) 2012-09-14 2019-09-24 Valeant Pharmaceuticals International, Inc. Teeth Whitening Method
CA2891291A1 (en) 2012-11-12 2014-05-15 Moontunes, Inc. Systems and methods for communicating a live event to users using the internet
US20140276354A1 (en) 2013-03-14 2014-09-18 Klox Technologies Inc. Biophotonic materials and uses thereof
WO2014197847A1 (en) * 2013-06-07 2014-12-11 The Regents Of The University Of California Methods and systems of treating wounds
KR20160029795A (en) 2013-07-03 2016-03-15 클록스 테크놀로지스 인크. Biophotonic Compositions Comprising a Chromophore and a Gelling Agent for Treating Wounds
US20150065943A1 (en) * 2013-08-27 2015-03-05 Matthew DeBow Method to Accelerate Healing
EP3125963B1 (en) 2014-04-01 2019-11-20 Klox Technologies Inc. Tissue filler compositions and methods of use
US10153510B2 (en) 2014-06-23 2018-12-11 University Of Kentucky Research Foundation Non-aqueous redox flow batteries including 3,7-perfluoroalkylated phenothiazine derivatives
JP6683686B2 (en) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド Channel regulator
AU2015337786B2 (en) 2014-10-31 2020-03-26 Klox Technologies Inc. Photoactivatable fibers and fabric media

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090788A (en) * 1997-07-28 2000-07-18 Dermatolazer Technologies Ltd. Phototherapy based method for treating pathogens and composition for effecting same
US6107466A (en) * 1996-09-19 2000-08-22 The General Hospital Corporation Acceleration of wound healing by photodynamic therapy
US6420455B1 (en) * 1999-06-18 2002-07-16 3M Innovative Properties Company Antimicrobial composition containing photosensitizers articles, and methods of use
US20020187935A1 (en) * 2000-02-11 2002-12-12 Redmond Robert W. Photochemical tissue bonding

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE488945C (en) * 1924-09-12 1930-01-25 I G Farbenindustrie Akt Ges Process for the preparation of aminoalkylamino substitution products of the azine, oxazine and thiazine series
EP0637976B2 (en) 1992-04-30 2002-10-16 Eastman Dental Institute Medicament for disinfection of the oral cavity
DE4220736A1 (en) * 1992-06-25 1994-01-05 Puetter Medice Chem Pharm Inclusion complexes of polymerized cyclodextrins with pharmaceutically active substances
AU1824300A (en) 1998-11-23 2000-06-13 Linden Biotechnology, Inc. Combination products of a guanylate cyclase inhibitor and a local anesthetic forpain relief
AU2314799A (en) * 1999-01-08 2000-07-24 David A. Browdie Tissue adhesive for treating vigorously bleeding surfaces
CN1108156C (en) 1999-03-26 2003-05-14 夏志陶 Long-acting analgesic used mainly for operational cut and traumatic wound
EP2335634A1 (en) 2000-02-11 2011-06-22 The General Hospital Corporation Photochemical tissue bonding
GB0113121D0 (en) * 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
GB0118251D0 (en) * 2001-07-26 2001-09-19 Photocure Asa Method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107466A (en) * 1996-09-19 2000-08-22 The General Hospital Corporation Acceleration of wound healing by photodynamic therapy
US6090788A (en) * 1997-07-28 2000-07-18 Dermatolazer Technologies Ltd. Phototherapy based method for treating pathogens and composition for effecting same
US6420455B1 (en) * 1999-06-18 2002-07-16 3M Innovative Properties Company Antimicrobial composition containing photosensitizers articles, and methods of use
US20020187935A1 (en) * 2000-02-11 2002-12-12 Redmond Robert W. Photochemical tissue bonding

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10160958B2 (en) 2005-04-11 2018-12-25 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US11781119B2 (en) 2005-04-11 2023-10-10 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US11345899B2 (en) 2005-04-11 2022-05-31 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US10731139B2 (en) 2005-04-11 2020-08-04 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US11598767B2 (en) 2009-06-25 2023-03-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US10823727B2 (en) 2009-06-25 2020-11-03 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2010151831A1 (en) * 2009-06-25 2010-12-29 Savient Pharmaceuticals, Inc. Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout
US11639927B2 (en) 2009-06-25 2023-05-02 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US11982670B2 (en) 2009-06-25 2024-05-14 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US12188927B2 (en) 2009-06-25 2025-01-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
WO2023229659A3 (en) * 2021-10-21 2024-03-14 The General Hospital Corporation Photonic antimicrobial wound surface dressing
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Also Published As

Publication number Publication date
WO2006032847A1 (en) 2006-03-30
JP2008513424A (en) 2008-05-01
ATE486860T1 (en) 2010-11-15
DE602005024590D1 (en) 2010-12-16
ES2358760T3 (en) 2011-05-13
DK1797053T3 (en) 2011-02-21
US20110028459A1 (en) 2011-02-03
JP5118967B2 (en) 2013-01-16
EP1797053B1 (en) 2010-11-03
EP1797053A1 (en) 2007-06-20
US7407953B2 (en) 2008-08-05
CY1111177T1 (en) 2015-06-11
PT1797053E (en) 2011-02-09
GB0420888D0 (en) 2004-10-20
US20070161625A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
US7407953B2 (en) Wound healing
KR0178277B1 (en) The pharmaceutical compositions for the detection and treatment of malignant and non-malignant lesion using by photochemotherapeutic method
JP5814508B2 (en) Use of aminolevulinic acid and its derivatives
JP4740524B2 (en) Heat-responsive mucoadhesive pharmaceutical-carrier composition
JP3506701B2 (en) Wound healing composition, its preparation and use
Szeimies et al. History of photodynamic therapy in dermatology
JP5689573B2 (en) Improved topical drugs and methods for photodynamic therapy of disease
NZ251284A (en) Use of a protoporphyrin ix precursor (preferably 5-aminolevulinic acid) to prepare pharmaceutical compositions
US7407948B2 (en) Photosensitisers and their uses
EP1320383B1 (en) Photosensitisers
Dillon et al. In vitro and in vivo protection against phototoxic side effects of photodynamic therapy by radioprotective agentswr–2721 andwr–77913
US20160220674A1 (en) Method of treating onychomycosis
RU2672564C2 (en) Methods of treatment and prevention of diseases of eyes, disorders and pathological conditions by melanin and analogs, precoursors and derivatives of melanin
FR2613617A1 (en) MEDICINAL AGENTS FOR THE PREVENTION AND THERAPY OF SKIN CUTANEOUS BURNS CONTAINING 2,6-DIMETHYL-3,5-DIETHOXYCARBONYL-1,4-DIHYDROPYRIDINE AS ACTIVE INGREDIENT
BRPI0514364B1 (en) LOW CONCENTRATION PHOTOSENSITIZING FORMULATION AND LOW CONCENTRATION THERAPY METHOD FOR DISEASE PDT TREATMENT
WO1998013038A1 (en) Subepithelial turbidity inhibitor
US12239727B2 (en) Compositions for use in the treatment of photosensitivity
US20240173414A1 (en) Photodynamic therapy comprising two light exposures at different wavelengths
RU2455039C1 (en) Method of photodynamic therapy of malignant growths
US20030083324A1 (en) Photosensitizing ointment
JP2009263317A (en) Therapeutic agent for skin disease
RomiszewskA et al. The use of 5-aminolevulinic acid and its derivatives in photodynamic therapy and diagnosis
WO2002011539A1 (en) Methods and compositions for treating skin ulcers by topical photodynamic therapy
US20050265954A1 (en) Novel association, a method of its preparation and its uses
JPH02311458A (en) Adamantyl ester of 2,6-dimethyl-1,4-dihydropyridine- 3,5-dicarboxylic acid

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION